Key Points
- Bruker VP Mark Munch sold 2,000 shares at an average price of $52.87, totaling $105,740. He retained 134,806 shares after the transaction, a 1.46% reduction in his position.
- Bruker shares opened at $60.67 and have gained 8.8%, trading between $30.09 and $65.30 over the past year. The company recently exceeded quarterly EPS expectations, reporting $0.49 versus the $0.38 consensus, while revenue rose 5.2% year over year.
- Analysts have a consensus “Hold” rating and a $57 price target, despite several firms raising their targets. Institutional investors own 79.52% of Bruker, and the company declared a quarterly dividend of $0.05 per share.
Bruker Corporation (NASDAQ:BRKR - Get Free Report) VP Mark Munch sold 2,000 shares of the firm's stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the sale, the vice president owned 134,806 shares of the company's stock, valued at $7,127,193.22. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Bruker Stock Up 8.8%
Shares of NASDAQ:BRKR opened at $60.67 on Thursday. Bruker Corporation has a fifty-two week low of $30.09 and a fifty-two week high of $65.30. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The firm's 50-day simple moving average is $58.09 and its 200-day simple moving average is $49.66. The company has a market cap of $9.24 billion, a price-to-earnings ratio of -86.67, a PEG ratio of 1.71 and a beta of 1.26.
Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.11. The firm had revenue of $838.50 million during the quarter, compared to analysts' expectations of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The firm's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts predict that Bruker Corporation will post 2.12 earnings per share for the current year.
Bruker Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 21st. Bruker's dividend payout ratio (DPR) is currently -28.57%.
Hedge Funds Weigh In On Bruker
Several hedge funds have recently added to or reduced their stakes in the business. Pallas Capital Advisors LLC purchased a new stake in Bruker in the 2nd quarter worth approximately $570,746,000. Edmond DE Rothschild Holding S.A. purchased a new position in shares of Bruker during the 2nd quarter worth $169,899,000. Franklin Resources Inc. boosted its holdings in shares of Bruker by 317.7% during the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company's stock worth $108,796,000 after purchasing an additional 1,756,460 shares during the last quarter. Primecap Management Co. CA acquired a new position in Bruker in the second quarter valued at $53,145,000. Finally, Bank of New York Mellon Corp acquired a new position in Bruker in the second quarter valued at $44,839,000. 79.52% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages recently weighed in on BRKR. TD Cowen reaffirmed a "hold" rating on shares of Bruker in a report on Wednesday, July 15th. Wolfe Research initiated coverage on shares of Bruker in a research note on Monday, June 1st. They set a "peer perform" rating on the stock. Leerink Partners raised their price objective on shares of Bruker from $60.00 to $70.00 and gave the company an "outperform" rating in a research note on Tuesday, July 7th. Barclays boosted their price objective on shares of Bruker from $53.00 to $60.00 and gave the stock an "overweight" rating in a report on Wednesday, June 24th. Finally, Citigroup dropped their target price on shares of Bruker from $60.00 to $53.00 and set a "hold" rating for the company in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $57.00.
View Our Latest Analysis on Bruker
Bruker Company Profile
(
Get Free Report)
Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.
The company's product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
